GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » Debt-to-EBITDA

PALI (Palisade Bio) Debt-to-EBITDA : -0.01 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Palisade Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.06 Mil. Palisade Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil. Palisade Bio's annualized EBITDA for the quarter that ended in Mar. 2025 was $-8.91 Mil. Palisade Bio's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Palisade Bio's Debt-to-EBITDA or its related term are showing as below:

PALI's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.15
* Ranked among companies with meaningful Debt-to-EBITDA only.

Palisade Bio Debt-to-EBITDA Historical Data

The historical data trend for Palisade Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Debt-to-EBITDA Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
-0.14 -0.01 -0.03 -0.03 -0.01

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.03 -0.03 -0.01 -0.01

Competitive Comparison of Palisade Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Palisade Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Palisade Bio's Debt-to-EBITDA falls into.


;
;

Palisade Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Palisade Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.169 + 0) / -14.423
=-0.01

Palisade Bio's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.058 + 0) / -8.912
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Palisade Bio  (NAS:PALI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Palisade Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio Business Description

Traded in Other Exchanges
N/A
Address
7750 El Camino Real, Suite 2A, Carlsbad, CA, USA, 92009
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley officer: Chief Financial Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones officer: Chief Medical Officer 70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae officer: Chief Operating Officer 675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam director, officer: Chief Executive Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson officer: Chief Medical Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center 10 percent owner 2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei director P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter director, officer: Executive Chairman 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma director 14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142